Pain in irritable bowel syndrome: Does anything really help?
- PMID: 34859929
- PMCID: PMC9017689
- DOI: 10.1111/nmo.14305
Pain in irritable bowel syndrome: Does anything really help?
Abstract
Pain relief remains a significant challenge in the management of irritable bowel syndrome (IBS): "Does anything really help relieve the pain in patients with IBS?". Interventions aimed at pain relief in patients with IBS include diet, probiotics or antibiotics, antidepressants, antispasmodics, and drugs targeting specific gastrointestinal receptors such as opioid or histamine receptors. In the systematic review and meta-analysis published in this journal, Lambarth et al. examined the literature on the role of oral and parenteral anti-neuropathic agents in the management of pain in patients with IBS. This review article appraises their assessment of the efficacy of the anti-neuropathic agents amitriptyline, pregabalin, gabapentin, and duloxetine in the relief of abdominal pain or discomfort, and impact on overall IBS severity and quality of life. This commentary provides an update of current evidence on the efficacy of the dietary and pharmacological treatments that are available or in development, as well psychological and cognitive behavioral therapy for pain in IBS. Advances in recent years augur well for efficacious treatments that may expand the therapeutic arsenal for pain in IBS.
Keywords: antispasmodics; hypnotherapy; neuromodulators; peppermint oil; psychotherapy.
© 2021 John Wiley & Sons Ltd.
Conflict of interest statement
Comment on
-
Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis.Neurogastroenterol Motil. 2022 Jan;34(1):e14289. doi: 10.1111/nmo.14289. Epub 2021 Nov 10. Neurogastroenterol Motil. 2022. PMID: 34755926
Similar articles
-
Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis.Neurogastroenterol Motil. 2022 Jan;34(1):e14289. doi: 10.1111/nmo.14289. Epub 2021 Nov 10. Neurogastroenterol Motil. 2022. PMID: 34755926
-
Dietary and pharmacological treatment of abdominal pain in IBS.Gut. 2017 May;66(5):966-974. doi: 10.1136/gutjnl-2016-313425. Epub 2017 Feb 23. Gut. 2017. PMID: 28232472 Review.
-
Treatment of irritable bowel syndrome.J Clin Pharm Ther. 2011 Jun;36(3):275-82. doi: 10.1111/j.1365-2710.2010.01177.x. Epub 2010 Aug 24. J Clin Pharm Ther. 2011. PMID: 21545610 Review.
-
Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.Gastroenterology. 2020 Jan;158(1):123-136. doi: 10.1053/j.gastro.2019.08.026. Epub 2019 Aug 27. Gastroenterology. 2020. PMID: 31470006 Clinical Trial.
-
Treatment of abdominal pain in irritable bowel syndrome.J Gastroenterol. 2014 Aug;49(8):1193-205. doi: 10.1007/s00535-014-0966-7. Epub 2014 May 21. J Gastroenterol. 2014. PMID: 24845149 Review.
Cited by
-
Peripheral CRF-R1/CRF-R2 antagonist, astressin C, induces a long-lasting blockade of acute stress-related visceral pain in male and female rats.Peptides. 2022 Nov;157:170881. doi: 10.1016/j.peptides.2022.170881. Epub 2022 Sep 19. Peptides. 2022. PMID: 36185037 Free PMC article.
-
Differential roles of serotonin receptor subtypes in regulation of neurotrophin receptor expression and intestinal hypernociception.Histol Histopathol. 2024 Jul;39(7):903-919. doi: 10.14670/HH-18-687. Epub 2023 Dec 11. Histol Histopathol. 2024. PMID: 38108436
-
Intracerebroventricular administration of TRH Agonist, RX-77368 alleviates visceral pain induced by colorectal distension in rats.Peptides. 2024 May;175:171181. doi: 10.1016/j.peptides.2024.171181. Epub 2024 Feb 27. Peptides. 2024. PMID: 38423212 Free PMC article.
-
Heart Rate Variability-An Index of the Efficacy of Complementary Therapies in Irritable Bowel Syndrome: A Systematic Review.Nutrients. 2022 Aug 22;14(16):3447. doi: 10.3390/nu14163447. Nutrients. 2022. PMID: 36014953 Free PMC article.
-
FAAH inhibitor URB597 shows anti-hyperalgesic action and increases brain and intestinal tissues fatty acid amides in a model of CRF1 agonist mediated visceral hypersensitivity in male rats.Neurogastroenterol Motil. 2024 Dec;36(12):e14927. doi: 10.1111/nmo.14927. Epub 2024 Sep 30. Neurogastroenterol Motil. 2024. PMID: 39344695 Free PMC article.
References
-
- Lambarth A, Zarate-Lopez N, Fayaz A. Oral and parenteral anti-neuropathic agents for the management of pain and discomfort in irritable bowel syndrome: A systematic review and meta-analysis. Neurogastroenterol Motil. 2021:e14289. - PubMed
-
- Black CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117–131. - PubMed
-
- Camilleri M. Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. Jama. 2021;325(9):865–877. - PubMed
-
- Camilleri M, Boeckxstaens G. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017;66(5):966–974. - PubMed
-
- Wald A Constipation: Advances in Diagnosis and Treatment. Jama. 2016;315(2):185–191. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical